The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1569
ISSUE 1569
April 8, 2019
Drugs for Chronic Heart Failure
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
April 8, 2019 (Issue: 1569)
Patients with a left ventricular ejection fraction (LVEF)
≤40% are considered to have heart failure with reduced
ejection fraction (HFrEF). Patients with a LVEF ≤50%
and symptoms of heart failure are considered to have
heart failure with preserved ejection fraction (HFpEF).
There is little evidence that drug treatment improves
clinical outcomes in patients with HFpEF.
... more
- P Rossignol et al. Heart failure drug treatment. Lancet 2019; 393:1034.
- CW Yancy et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:e240.
- CW Yancy et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136:e137.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2017; September 18 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Drug Interactions from The Medical Letter. Available at: www. medicalletter.org/subDIO.
- H Svanström et al. Association of treatment with losartan vs candesartan and mortality among patients with heart failure. JAMA 2012; 307:1506.
- MA Konstam et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374:1840.
- FDA. Drug development and drug interactions: table of substrates, inhibitors and inducers. Available at www.fda.gov. Accessed March 27, 2019.
- Sacubitril/valsartan (Entresto) for heart failure. Med Lett Drugs Ther 2015; 57:107.
- JJ McMurray et al. Angiotensin-neprilysin versus enalapril in heart failure. N Engl J Med 2014; 371:993.
- O Vardeny et al. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail 2014; 2:663.
- F Zannad et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364:11.
- B Pitt et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.
- AL Taylor et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. New Engl J Med 2004; 351:2049.
- K Swedberg et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376:875.
- Ivabradine (Corlanor) for heart failure. Med Lett Drugs Ther 2015; 57:75.
- MY Yacoob et al. The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: a meta-analysis. Hypertension 2013; 62:375.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Chronic Heart Failure
Article code: 1569a
Electronic, downloadable article - $45
Article code: 1569a
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian